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Abstract
Group A Streptococcus (GAS) is a Gram-positive human pathogen best known for causing pharyngeal and mild skin
infections. However, in the 1980’s there was an increase in severe GAS infections including cellulitis and deeper tissue
infections like necrotizing fasciitis. Particularly striking about this elevation in the incidence of severe disease was that those
most often affected were previously healthy individuals. Several groups have shown that changes in gene content or
regulation, as with proteases, may contribute to severe disease; yet strains harboring these proteases continue to cause mild
disease as well. We and others have shown that group A streptococci (MGAS5005) reside within biofilms both in vitro and in
vivo. That is to say that the organism colonizes a host surface and forms a 3-dimensional community encased in a protective
matrix of extracellular protein, DNA and polysaccharide(s). However, the mechanism of assembly or dispersal of these
structures is unclear, as is the relationship of these structures to disease outcome. Recently we reported that allelic
replacement of the streptococcal regulator srv resulted in constitutive production of the streptococcal cysteine protease
SpeB. We further showed that the constitutive production of SpeB significantly decreased MGAS5005Dsrv biofilm formation
in vitro. Here we show that mice infected with MGAS5005Dsrv had significantly larger lesion development than wild-type
infected animals. Histopathology, Gram-staining and immunofluorescence link the increased lesion development with lack
of disease containment, lack of biofilm formation, and readily detectable levels of SpeB in the tissue. Treatment of
MGAS5005Dsrv infected lesions with a chemical inhibitor of SpeB significantly reduced lesion formation and disease spread
to wild-type levels. Furthermore, inactivation of speB in the MGAS5005Dsrv background reduced lesion formation to wild-
type levels. Taken together, these data suggest a mechanism by which GAS disease may transition from mild to severe
through the Srv mediated dispersal of GAS biofilms.
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Introduction
Cellulitis is a soft tissue infection of the dermis that extends into
subcutaneous tissues and can be either non-necrotizing or more
severe and associated with tissue necrosis (abscesses or exudates)
[1–3]. This acute spreading infection can arise from a pre-existing
infection, an underlying skin condition (eczema) or a break in the
epithelium, and can occur at any site on the body [2–4]. Group A
Streptococcus (GAS) is a Gram-positive human pathogen that is
capable of causing a variety of infections in the human host, and is
often associated with cellulitis and other soft tissue infections
ranging in severity from impetigo to severe necrotizing fasciitis [5–
11]. Serotype M1 GAS strains have become the most common
cause of invasive GAS infections following their sudden increase in
frequency and disease severity in the mid-1980’s [12]. Non-
invasive GAS infections, comprised of mostly throat and skin
infections, are less severe but have a higher rate of occurence, with
over ten million cases diagnosed each year [13].
While GAS biofilms have been observed both in vivo and in vitro,
the composition and regulation of these structures during a soft
tissue infection have not been well defined [14–17]. Akiyama et al.
(2003) made some of the first observations of GAS microcolony
formation in murine tissue infections, in which the microcolony
appeared to be surrounded by glycocalyx. Similar structures were
also identified in human impetigo specimens, suggesting that GAS
biofilms play an important role in soft tissue pathogenesis and,
subsequently, treatment of these infections [14]. In vitro grown
biofilms have shown that DNA and proteins, not carbohydrates,
are necessary components for biofilm formation, suggesting that
the composition of these structures may vary between strains or in
the presence of an active immune response [16]
One GAS virulence factor, SpeB, is an extracellular cysteine
protease capable of cleaving both host and bacterial proteins and
contributing to tissue damage and dissemination [17–20]. In vitro,
SpeB has been shown to play a role in GAS evasion of the host
immune response by preventing immunoglobulin and C3b, a
component of the complement pathway, opsonization [21,22].
Clearance of GAS by neutrophils and macrophages may also be
inhibited in the presence of SpeB; it has been previously shown in
vitro that SpeB can induce apoptosis in both of these phagocytic
immune cells [23,24]. SpeB activates host proteins through
cleavage, such as interleukin-1b precursor and pro-matrix
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in GAS dissemination from the site of infection through increased
inflammation and tissue damage, respectively [17,19]. The
cleavage and degradation of extracellular matrix proteins by
SpeB, such as tissue integrity components fibronectin and
vitronectin, also contributes to tissue damage and bacterial
colonization [18]. In addition to host proteins, SpeB degrades a
wide variety of GAS-produced proteins and virulence factors,
including M protein, protein F1, C5a peptidase, protein H and
SmeZ [18]. SpeB cleavage of the adherence factors M protein and
protein F1 is thought to reduce both bacterial and host cell-to-cell
interactions [25–27]. Cleavage-activated C5a peptidase degrades
C5a while free protein H binds C3, inhibiting opsonization by the
complement pathway [26]. Finally, proteolysis of the superantigen
SmeZ limits the immune response [18].
Recently, we have shown that allelic replacement of the
streptococcal regulator of virulence (Srv), a putative transcriptional
regulator, resulted in the constitutive production of SpeB [28,29].
While speB is highly conserved and present in almost all strains of
GAS, speB expression is variable between strains [30]. Production
of SpeB in MGAS5005 planktonic culture is detected during late
exponential and early stationary phases of growth, however, high
levels of SpeB are present in MGAS5005Dsrv culture after only
two hours of growth [29,31].
Interestingly, loss of Srv also led to a significant reduction in the
ability of GAS to form biofilms. As hypothesized by Donlan and
Costerton, a biofilm is a bacterial sessile community encased in a
matrix of extracellular polymeric substances and attached to a
substratum or interface [32]. Biofilms are believed to be inherently
tolerant to host defenses and antibiotic therapies and often linked
to chronic illness due to impaired clearance [33,34]. Some
estimates suggest that upwards of 60% of all bacterial infections
involve biofilms, including soft tissue infection and necrotizing
fasciitis [14,32,35]. There is a growing understanding of the
importance of biofilm formation in GAS disease as well [14–
16,36–40]. In our in vitro work we have shown that either allelic
replacement of SpeB in the MGAS5005Dsrv background or
chemical inhibition of SpeB with the cysteine protease inhibitor
E64 restored biofilm formation by the MGAS5005Dsrv strain to
wild-type levels [16,41].
Taken together, these observations suggest two possible
hypotheses for the fate of the MGAS5005Dsrv strain in a murine
model of soft tissue infection. One, the loss of biofilm formation by
MGAS5005Dsrv in vitro would translate into increased clearance in
vivo and decreased virulence. Two, the constitutive production of
SpeB by MGAS5005Dsrv would lead to increased virulence and
tissue damage. To test these hypotheses, we challenged mice in a
subcutaneous model of skin infection. We demonstrated that allelic
replacement of srv resulted in increased virulence. This increased
virulence was associated with increased SpeB detection and
decreased evidence of MGAS5005Dsrv biofilm formation. Allelic
replacement of speB in the MGAS5005Dsrv background reduced
virulence to wild-type levels and evidence of biofilm formation in
vivo was observed. Furthermore, local treatment of the infection
with the cysteine protease inhibitor E64 significantly reduced
virulence.
Results
Allelic replacement of srv resulted in increased virulence
in a murine subcutaneous infection model
To assess the loss of srv in an in vivo infection model, groups of 10
mice were inoculated with ,2610
8 CFU of either MGAS5005 or
MGAS5005Dsrv. The area of the lesion, average percentage of
weight loss, and bacterial load recovered were recorded. In
general, MGAS5005 infected animals developed a subcutaneous
abscess 1 dpi that erupted as a measurable cutaneous lesion by
2 dpi (Figure 1A). In contrast, MGAS5005Dsrv infected animals
developed readily visible lesions by 2 dpi that were significantly
larger than those observed in MGAS5005 infected animals
(Figure 1A and B). This trend continued with significantly larger
lesions observed in MGAS5005Dsrv infected animals throughout
the course of the experiment with lesions exceeding 40 mm
2 in
some cases (Figure 1A and B). A similar trend was observed when
the average weight lost between the two groups of animals was
compared. Both groups of animals lost on average 10% of their
body weight by 1 dpi (Figure 2). By day 3, MGAS5005Dsrv
infected animals weighed significantly less than their wild-type
infected counterparts (Figure 2). While not always significant, the
average recorded weight of MGAS5005Dsrv infected animals was
less than MGAS5005 infected animals over the 8 day experiment
(Figure 2). To determine if this increase in virulence might be due
to increased bacterial load, three additional mice for each
experimental group were infected as described above. Lesions
and the underlying abscess were surgically excised, homogenized,
and the bacteria were enumerated. Even though larger lesions
were excised from MGAS5005Dsrv infected animals, the total
bacterial CFU recovered (Figure 3A), as well as bacterial CFU/g
(Figure 3B), was not statistically different between MGAS5005 and
MGAS5005Dsrv infected animals at 1, 3, or 8 dpi.
Figure 1. Allelic replacement of srv lead to increased lesion size
in a murine subcutaneous infection model. (A) Groups of 10 mice
(Crl:SKH1-hrBR) were challenged subcutaneously with ,2.0610
8 CFU
(0.1 ml) of either MGAS5005 or MGAS5005Dsrv. Representative images
of lesions formed at 1, 3 and 8 dpi are shown. (B) The area of the lesion
formed (mm
2) was measured with a caliper daily. Lesions formed by
MGAS5005Dsrv were significantly larger (p#0.05) than those formed by
MGAS5005 by 2 dpi (Student’s t-test).
doi:10.1371/journal.pone.0018984.g001
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necrosis in MGAS5005Dsrv infected samples
To further investigate the differences in virulence observed, 3
mice per experimental group were infected as before and
histopathology was performed using sections from MGAS5005
and MGAS5005Dsrv lesions collected at days 1, 3, and 8 post-
infection. 10 mm sections were subjected to H&E staining to
observe the infiltrate present and the extent of damage at the site
of infection (Figure 4). MGAS5005 infected samples showed the
clear development of a subcutaneous abscess, characterized by
edema well delineated by fibrin and polymorphonuclear leuko-
cytes (PMNs) (Figure 4A and B). While the extent of ulceration
varied, cutaneous lesions developed over the next three days with
some degree of epithelial reformation (healing) observed by 8 dpi
(Figure 4C). In contrast, MGAS5005Dsrv infected samples showed
evidence of edema and ulceration by 1 dpi, however, the edema
was not well delineated by fibrin accumulation and PMN influx
(Figure 4D). As recorded photographically in Figure 1, the
MGAS5005Dsrv lesions continued to develop over time with little
signs of healing or resolution (Figure 4 E and F).
SpeB detected throughout MGAS5005Dsrv infected
tissue
As mentioned previously, our in vitro work demonstrated that
allelicreplacement of srv resulted inconstitutiveproduction of SpeB.
To begin to test thehypothesisthat the increased virulenceobserved
of MGAS5005Dsrv was due to SpeB, we used immunofluorescent
microscopy to look for the presence of GAS and SpeB in the
infected tissue. Given that a significant difference in lesion size was
observedby2 dpi,weelectedtostudytissuesamplescollected1 dpi.
Adjacent 10 mm sections of lesion tissue to those collected for
histology and Gram-stain were obtained and stained with rabbit
anti-SpeB sera, goat anti-GAS sera, and fluorescent secondary
antibody conjugates. DIC/fluorescent images showed GAS distrib-
uted throughout MGAS5005 and MGAS5005Dsrv infected samples
(Figure 5A and B). Randomly selected areas throughout the
abscesses were chosen for closer examination at 206magnification
(Figure 5A and B i–iv). While MGAS5005 was readily detected in
the 206 images, SpeB was rarely observed (Figure 5Ai–iv).
However, SpeB was readily detected in the MGAS5005Dsrv
infected samples (Figure 5Bi–iv). In an effort to quantify the signal
observed, ImageJ (rsbweb.nih.gov) was used to calculate the pixel
area from the four representative 206images provided (Figure 5C).
While the images shown are from single mouse infections, they are
representative of the images obtained from eachof the experimental
groups. While both infections showed similar staining of anti-GAS,
anti-SpeB staining was significantly increased in images collected
from the MGAS5005Dsrv infected tissue sample (Figure 5C).
Gram-staining revealed microcolonies indicative of
biofilms in MGAS5005 infected samples
Based on our in vitro data, we hypothesized that MGAS5005Dsrv
would be largely unable to form biofilms in vivo. We and other
researchers have shown that microcolonies, detected by Gram-
staining and other methods, are evidence of in vivo biofilms
[14,15,17,42]. 10 mm sections of lesion tissue collected 1, 3, and
8 dpi were subjected to Gram-staining. MGAS5005 microcolonies
were clearly observed by 3 dpi (Figure 6A). Larger microcolony
formations were observed 8 dpi in MGAS5005 infected samples
(Figure 6A). However, no comparable structures were observed in
Gram-stained MGAS5005Dsrv infected samples (Figure 6B).
Instead, MGAS5005Dsrv appeared randomly distributed through-
out the samples.
Allelic replacement of speB in the MGAS5005Dsrv
background significantly reduced lesion formation in
infected animals and restored microcolony formation
We have recently shown that allelic replacement of speB in the
MGAS5005Dsrv background restored biofilm formation and
Figure 2. Average percentage of mouse weight loss following
GAS infection. Groups of 10 mice were challenged subcutaneously
with ,2.0610
8 CFU (0.1 ml) of either MGAS5005 or MGAS5005Dsrv.
The percentage of weight lost was monitored for 8 dpi. Mice infected
with MGAS5005Dsrv weighed significantly less on 5/8 dpi (*p#0.05).
doi:10.1371/journal.pone.0018984.g002
Figure 3. Bacterial load recovered from excised lesions. Lesions
from mice infected with either MGAS5005 or MGAS5005Dsrv (n=3
mice/strain) were excised at 1, 3 and 8 dpi, weighed and homogenized
for replicate plating. No significant difference in (A) total CFU recovered
or (B) CFU/g was observed at 1, 3, and 8 dpi.
doi:10.1371/journal.pone.0018984.g003
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Based on the data presented here we hypothesize that the
MGAS5005DsrvDspeB strain would be less virulent and microcol-
ony formation in the infected lesion tissue samples would be
observed. Mice were infected as before using ,2610
8 CFU of
MGAS5005DsrvDspeB (n=10). Lesion formation by the
MGAS5005DsrvDspeB strain resembled that of MGAS5005 and
was significantly less than the size of lesions observed in
MGAS5005Dsrv infected samples (Figure 7). Comparable bacterial
CFU was recovered at 8 dpi from MGAS5005, MGAS5005Dsrv,
and MGAS5005DsrvDspeB infected tissue (data not shown). Gram-
stained 10 mm sections of MGAS5005DsrvDspeB infected samples
revealed the presence of microcolonies of varying sizes 8 dpi
(Figure 8).
Chemical inhibition of SpeB in vivo during
MGAS5005Dsrv infection significantly reduces lesion
formation
Our data indicate that increased virulence of the
MGAS5005Dsrv strain is due to the constitutive production of
SpeB documented in vitro. Thus, we hypothesized that chemical
inhibition of SpeB in vivo during infection would reduce lesion
formation and virulence. To test this hypothesis, the infecting dose
of MGAS5005Dsrv was suspended in 333 mM of E64 (0.1 mL).
E64 is a commercially available inhibitor of cysteine proteases
[43,44]. Mice were infected as before and monitored for 8 days
(n=10). The overall area of the lesions formed was reduced and
was significantly less than lesions formed by MGAS5005Dsrv
infected animals on days 4–8 post-infection (Figure 9A). To
determine if lesion size could be reduced even further, E64 was
mixed with the inoculating dose of MGAS5005Dsrv as before, and
infected mice received injections of 0.1 mL 333 mM E64 each day
post-infection. Injections were delivered directly to the subcuta-
neous abscess. Lesion formation was returned to wild-type levels
and significantly less than in untreated MGAS5005Dsrv infected
animals days 2–8 post-infection (Figure 9B). Addition of E64 to
MGAS5005 infected samples did not result in a statistically
significant change in lesion size over the course of infection (data
not shown).
To rule out the possibility that the reduced lesion size was due to
the therapeutic effects of lavage, animals were infected
MGAS5005Dsrv as before and receive daily 0.1 mL injections of
saline directly to the abscess. While lesion size was reduced, it was
not reduced to the extent of the E64 treated animals (Figure 10).
Thus, while lavage has a therapeutic effect, chemical inhibition of
SpeB by E64 in vivo significantly reduces the virulence of
MGAS5005Dsrv.
Discussion
Previously, we have shown that the loss of the stand-alone
response regulator Srv in MGAS5005 resulted in significant
reduction of in vitro biofilm formation in both static and flow biofilm
assays [16,41]. Furthermore, MGAS5005Dsrv exhibited reduced
biofilm formation in vivo in a chinchilla model of otitis media [42].
The loss of biofilm formation by MGAS5005Dsrv was attributed to
constitutive production of the cysteine protease SpeB, as biofilm
formation was restored through either chemical inhibition of SpeB
in vitro or allelic replacement of speB in the MGAS5005Dsrv
background in both in vitro and in vivo biofilm models [16,41,42].
One long term goal of our laboratory is to understand the roleof the
GAS biofilm in disease. In our recent work utilizing a chinchilla
model of otitis media, we hypothesized that the biofilm deficient
MGAS5005Dsrv strain would be readily cleared from the site of
infection due to the lack of the protective properties afforded by the
biofilm. However, we found that MGAS5005Dsrv persisted at the
site of infection for the duration of the experiment [42].
Furthermore, higher bacterial loads of MGAS5005Dsrv were
observed in middle ear effusions throughout the course of infection
compared to MGAS5005, and, while not statistically significant, the
mortality rate of MGAS5005Dsrv infected animals was higher [42].
Taken together, this data supports a hypothesis that dispersal of the
GAS biofilm by SpeB results in increased virulence. Here, we chose
to further explore this hypothesis in a murine soft tissue model of
infection. Based on our hypothesis, one of two outcomes was likely.
One, lack of biofilm formation in the soft tissue model would result
in the accelerated clearance of GAS from the site of infection.
Alternatively, dispersal of the GAS biofilm and the constitutive
production of SpeB would result in increased virulence and tissue
Figure 4. Histopathology of excised lesions from MGAS5005 and MGAS5005Dsrv infections. Lesions were surgically excised at days 1, 3,
and 8 post infection. 10 mm sections were subjected to H&E staining. Representative low-magnification images (26) from each time point are shown.
(A,B) Infection with MGAS5005 resulted in the formation of a subcutaneous abscess (arrow) that was well delineated by fibrin (pink border) and PMNs
(purple border). (C) By 8 dpi, the abscess had ruptured and formed a cutaneous lesion that showed signs of healing (arrow). (D) MGAS5005Dsrv
infection resulted in a cutaneous lesion (arrow). (D & E) Note the subcutaneous abscess was less contained by colocalized fibrin and PMNs (dashed
arrows). (E) The cutaneous lesion grew in size and did not show any appreciable healing by 8 dpi (F).
doi:10.1371/journal.pone.0018984.g004
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outcome.
The association of SpeB and increased lesion development has
been previously reported in other GAS infection models
[10,20,45–48]. For example, SpeB production was found to be
essential for establishing a murine skin infection that ultimately
resulted in systemic infection, reduced clearance by the innate
immune response, and increased mortality [10,20]. More recently,
Figure 5. Immunofluorescent antibody staining revealed detectable levels of SpeB throughout MGAS5005Dsrv infected tissue as
compared to MGAS5005 infected tissue. Subcutaneous abscesses from (A) MGAS5005 and (B) MGAS5005Dsrv infections were excised 1 dpi,
sectioned, and stained with rabbit anti-SpeB sera and goat anti-GAS sera, and the appropriate fluorescent secondary antibody conjugate. (A, B) DIC/
fluorescent images (46) from an MGAS5005 infected animal (A) and an MGAS5005Dsrv infected animal (B) show the distribution of GAS (red)
throughout the abscess. Randomly selected areas throughout the abscesses were examined for the colocalization of GAS and SpeB (206, i–iv).
MGAS5005 was readily detected (Ai–iv), but SpeB (green) was rarely detected in MGAS5005 infected samples (arrows, Aiii). In contrast, SpeB was
detected in the presence of MGAS5005Dsrv throughout the infected samples (Bi–iv). Colocalized SpeB and GAS appear yellow. Representative images
are shown. (C) Average total area of pixels (pixels
2) was calculated for anti-GAS and anti-SpeB staining in the representative images shown of
MGAS5005 and MGAS5005Dsrv. Comparable amounts of anti-GAS staining was observed, however, there is significantly more anti-SpeB staining in
MGAS5005Dsrv images compared to MGAS5005 (* p,0.01).
doi:10.1371/journal.pone.0018984.g005
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observed following a GAS skin infection in a humanized mouse
model [49]. Furthermore, addition of purified SpeB with either a
wild-type or DspeB M1 strain into a mouse air sac model of
infection led to accelerated and increased tissue necrosis, as well as
Figure 6. Gram-staining of lesion tissue sections revealed the
presence of MGAS5005 microcolonies (biofilms). 10 mm sections
of lesion tissue collected 1, 3, and 8 dpi were subjected to Gram-
staining. (A) MGAS5005 infected samples contained microcolonies of
adherent GAS which were visible by 3 dpi (arrows). These microcolonies
are reminiscent of biofilms and appeared to increase in size by 8 dpi. (B)
MGAS5005Dsrv infected samples contained randomly dispersed GAS
throughout the field of view. Microcolonies were largely absent. The
same view of single day images are shown at 606 and 1006
magnification. Representative images are shown.
doi:10.1371/journal.pone.0018984.g006
Figure 7. Allelic replacement of speB in the MGAS5005Dsrv
background resulted in significantly decreased lesion size.
Representative images of lesions formed in mice at 1, 3 and 8 days
following subcutaneous infection with ,2610
8 CFU (0.1 ml) of
MGAS5005DsrvDspeB. Lesion development (mm
2) was monitored over
8 days using a caliper (n=10 mice/strain). A significant reduction in
lesion size was observed in MGAS5005DsrvDspeB infected mice
(p,0.05). The size of lesions observed in MGAS5005 infected mice vs.
MGAS5005DsrvDspeB was not significantly different.
doi:10.1371/journal.pone.0018984.g007
Figure 8. Microcolony formation is observed in MGAS-
5005DsrvDspeB infected tissue. Representative images of Gram-
stained sections (10 mm thick) collected from two MGAS5005DsrvDspeB
infected mice at 8 dpi. MGAS5005DsrvDspeB microcolonies (arrows)
were present in the edema at the site of infection.
doi:10.1371/journal.pone.0018984.g008
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infection [47]. The DspeB M1 strain alone did not form a lesion of
any significance [47]. Thus, SpeB is a well appreciated and
increasingly understood virulence factor of GAS. However, there
are several observations presented here that provide new insight
into the biology of GAS and its pathogenesis.
Figure 9. Use of the chemical inhibitor of cysteine proteases E64 significantly reduced lesion size in MGAS5005Dsrv infected
animals. Representative images of lesions formed in mice at 1, 3 and 8 days following subcutaneous infection with ,2610
8 CFU of MGAS5005Dsrv.
(A) The infecting dose of MGAS5005Dsrv was suspended in 333 uM E64 (0.1 ml), and lesion development (mm
2) was monitored over 8 days (n=10
mice). A significant reduction in lesion formation was observed when E64 was inoculated with the infecting dose of MGAS5005Dsrv compared to
inoculation with MGAS5005Dsrv alone (p,0.05). (B) Following inoculation of animals with E64+MGAS5005Dsrv as before, an additional inoculation of
333 mM E64 (0.1 mL) was injected directly into the abscess each day following infection (n=10). A significant reduction in lesion size was observed
with E64 treated animals forming lesions roughly equivalent in size to untreated MGAS5005 infected animals.
doi:10.1371/journal.pone.0018984.g009
Figure 10. Daily wound irrigation not responsible for the reduction in lesion size observed in E64 treated animals. Lesion size in saline
treated animals (n=3) was significantly reduced at 5 and 6 dpi compared to MGAS5005Dsrv infected animals (p,0.05), however, lesions in saline
treated animals were statistically larger than those in E64 treated animals at 2–8 dpi (p,0.05).
doi:10.1371/journal.pone.0018984.g010
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MGAS5005 background leads to increased virulence coupled with
increased production of SpeB in vivo. Previously, regulation of speB
has been linked to several regulatory factors, including the two
component signal transduction system CovRS (also referred to as
CsrRS) [50–53]. This is particularly interesting because
MGAS5005 has been shown to produce a truncated, functionally
inactive CovS protein, which results in a loss of the histidine kinase
domain and the ability to phosphorylate CovR [48,54,55]. It
should be noted that this does not invalidate MGAS5005 as a
strain worthy of study. MGAS5005 was isolated from a patient
suffering from invasive disease. In fact, several recent studies have
shown evidence of GAS with covS non-functional mutations
isolated from in vivo systemic infections, suggesting that covS
mutants posses a selective advantage during invasive infections
[48,54,56–61]. Normally, CovS can also help to relieve CovR
repression and increase speB expression in response to stress
[62,63]. Complementation of MGAS5005 in trans with a
functional covS restored SpeB production [48]. Here, SpeB
production is restored through the allelic replacement of srv
suggesting that Srv is involved in the CovR mediated repression of
speB. Efforts are underway to understand this mechanism as are
studies to explore the function of Srv in strain backgrounds with a
functional CovS.
Second, loss of srv also results in a loss of biofilm formation in
vivo. This is observed in our Gram-stained sections which revealed
that MGAS5005 aggregated into microcolonies while
MGAS5005Dsrv was dispersed throughout the infected samples.
This change in phenotype is also due to the restored production of
SpeB as microcolony formation was observed in
MGAS5005DsrvDspeB infected samples. These results mimic what
we have recently observed in a chinchilla model of GAS otitis
media [42]. Thus, we now have evidence that biofilm formation is
not required for infection at two distinct host sites (skin and middle
ear), or at least not required given the means of inoculation used.
However, our data also suggests that MGAS5005 would naturally
form a biofilm upon infection. We envision a model where biofilm
formation is used for colonization of a host site and protection
from the innate immune response. Coordinate regulation of speB
by both CovR and Srv (and perhaps other regulators) would allow
for the controlled production of SpeB that would facilitate
dispersal of some portion of GAS from the biofilm to achieve
spread to another host site or susceptible host. Under this model,
loss of regulation of this system would lead to severe disease. It has
been hypothesized that downregulation of SpeB in DcovS strains
would prevent cleavage and degradation of virulence factors that
may aid in GAS transitioning from a localized to a systemic
infection [45,54,56,57,64,65]. It is interesting to speculate that the
selective advantage provided by natural mutations in covS is an
increase in the ability to form biofilms and a resulting increase in
the ability to colonize a host site. We have begun to test this
hypothesis and have found that allelic replacement of srv in a
normally CovS+ background in serotypes M1, M3, M12 and M18
resulted in decreased biofilm formation in vitro (data not shown).
Finally, we demonstrated that chemical inhibition of SpeB in vivo
resulted in a significant reduction in lesion formation. We utilized
the specific inhibitor of cysteine proteases E64, which irreversibly
binds the active thiol group of SpeB [43,44,66]. E64 is commonly
used as a cysteine protease inhibitor during in vitro assays, but this
is the first study to our knowledge to demonstrate the effects of E64
treatment on GAS infection in vivo [11,16,65,67,68]. Addition of
E64 to the MGAS5005Dsrv inoculum immediately prior to
infection significantly reduced lesion development, suggesting that
halting SpeB activity early during the course of infection may be
the most useful. Daily treatment of MGAS5005Dsrv infections with
E64 further reduced lesion development. Of course E64 may be
inhibiting other inflammatory elements at the site of infection
which contribute to lesion development. Taken together, this data
provides further support for therapeutics designed to modulate
SpeB and the host immune response to streptococcal infection.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Care and Usage Committee
of the Wake Forest University School of Medicine (Animal
Welfare Assurance #A3391-01). All procedures were performed
under isoflurane anesthesia, and all efforts were made to minimize
suffering.
Bacterial strains and growth conditions
MGAS5005 is a M1T1 serotype strain isolated from a case of
invasive GAS disease and has previously been used in several
studies of GAS pathogenicity [16,69]. The isogenic mutants
MGAS5005Dsrv and MGAS5005DsrvDspeB were generated by
allelic replacement as previously described [69–71]. Overnight
cultures grown in Todd Hewitt broth (Becton-Dickinson) supple-
mented with 2% yeast extract (THY) (Fisher Scientific) at 37uC,
5% CO2 were diluted into fresh THY and allowed to reach
logarithmic phase. Logarithmic cultures were washed 3 times in
16Dulbecco’s Phosphate Buffered Saline (DPBS) before infection.
Initial CFU of infectious dose was confirmed by serial dilutions
plated onto THY agar plates.
Murine subcutaneous infections
Studies were approved by the Animal Care and Use Committee
of Wake Forest University Health Sciences. Five-week-old,
outbred, immunocompetent, hairless female Crl:SKH1-hrBR mice
(Charles River) received subcutaneous injections of
,2.0610
8 CFU (0.1 ml) of either MGAS5005, MGAS5005Dsrv
or MGAS5005DsrvDspeB at the base of the neck. Mice that
received L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane
(E64) (Sigma) treatment were given ,2.0610
8 CFU
MGAS5005Dsrv resuspended in 333 mM E64 (0.1 ml) at the time
of infection. Those that were given daily treatments of E64
received 333 mM E64 (0.1 ml) injected at the site of infection
beginning 24 hours post infection. Area of the lesion formed at the
site of infection was measured daily using a caliper. The weight of
each mouse was recorded daily for up to 8 days following
infection, at which point the mice were euthanized and tissue at
the site of infection was excised. A random subset of lesions were
homogenized to determine the bacterial load (CFU/g) at 1, 3 and
8 days following infection. Tissue samples were also fixed for
paraffin embedding or snap frozen in liquid nitrogen and stored at
280uC.
Microscopy
Tissue samples were fixed in fresh 1% paraformaldehyde for
24 hours at 4uC and then stored in 70% ethanol at room
temperature until paraffin embedding. Adjacent 10 mm thick
sections were collected and used for hematoxylin and eosin
staining (H&E), Gram-staining, or immunofluorescence. Sections
were collected on positively charged slides and heat fixed at 85uC
for 10 minutes. Paraffin was removed from the tissue sections by
xylene and ethanol washes before samples were stored in 16
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eosin-phloxine and a standard H&E protocol. Taylor’s Brown-
Brenn modified Gram-stain was used for Gram-staining tissue
sections.
Immunofluorescence utilized double staining with the primary
antibodies rabbit anti-SpeB (1:100) (Toxin Technology, Inc.) and
goat anti-GAS (1:500) (US Biologicals); rabbit anti-Borrelia
burgdorferi (1:500) (US Biologicals) was used as a negative control.
Secondary antibodies used for double staining were Alexa Fluor-
488 donkey anti-rabbit (1:500) and Alexa Fluor-568 donkey anti-
goat (1:500) (Invitrogen). Samples were blocked in 1% bovine
serum albumin (BSA)-DPBS for 1 hour at room temperature.
Primary antibodies in 1% BSA-DPBS were applied to the samples
and incubated for 30 minutes at 37uC in a humidified chamber;
these same conditions were repeated for addition of the secondary
antibodies. A glass coverslip was fixed with ProLong Gold antifade
reagent (Invitrogen) and prepared samples were allowed to cure
overnight in the dark at room temperature. Images were captured
using a Nikon Eclipse TE300 Light Microscope (Nikon) and
QImaging Retiga-EXi camera (AES). ImageJ v1.43 software
(rsbweb.nih.gov) was used to analyze total pixel counts and store
images.
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